...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Biology, Agriculture and Healthcare >Comparative Analysis of Antimicrobial Resistance of Extended-Spectrum Beta-Lactamase Producers and Non-Extended-Spectrum Beta-Lactamase Producers among Bacterial Isolates in Accra, Ghana
【24h】

Comparative Analysis of Antimicrobial Resistance of Extended-Spectrum Beta-Lactamase Producers and Non-Extended-Spectrum Beta-Lactamase Producers among Bacterial Isolates in Accra, Ghana

机译：加纳阿克拉细菌分离株中广谱β-内酰胺酶生产者和非广谱β-内酰胺酶生产者的耐药性比较分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Antibiotic resistance may occur naturally but misuse of antibiotics in humans and animals is accelerating the process. One of the modes of resistant mechanism is the production of extended-spectrum beta-lactamases (ESBLs) by the bacteria. ESBLs are plasmid-mediated beta-lactamases that are capable of hydrolysing penicillins, cephalosporin and several non-beta-lactam antibiotics. This laboratory-based study sought to compare the rate of antimicrobial resistance between ESBL and non-ESBL-producers in Accra. Four hundred K . pneumoniae and E . coli isolates were collected at the Korle Bu Teaching Hospital and screened for ESBL and non-ESBL-producers using the combined disk method and Vitek 2 system. The minimal inhibition concentrations (MICs) for 17 commonly used antibiotics were determined using Vitek 2 System. The results indicated significant difference (P<0.05) between the antimicrobial resistance of ESBL-producers and non-ESBL producers except for amikacin and imipenem. The 198 non-ESBL phenotypes recorded relatively low antimicrobial resistance to cefotaxime 4(2%), ceftazidime 4(2%), nitrofurantoin 6(3%), amoxicillin/clavulanic acid 27(13.6%), gentamicin 34(17.2%) and ciprofloxacin 78(39.4%). In contrast, the 202 ESBL producers registered high antibiotic resistance to cefotaxime 197(97.5%), ceftazidime 175(86.6%), nitrofurantoin 94(46.5%), amoxicillin/clavulanic acid 64(31.7%), gentamicin 166(82.2%) and ciprofloxacin 161(79.7%). Cephalosporins and nitrofurantoin are suitable for the treatment of non-ESBL producers while imipenem and amikacin is the drug of choice for treating ESBL-producing infections. Evidence based antibiotic usage will help to control the spread of resistance by ESBL producers in Accra, Ghana. Also, there is the need to intensify research in the use of natural products to treat ESBL infections.
机译：抗生素耐药性可能自然发生，但在人畜中滥用抗生素正在加速这一过程。耐药机制的一种模式是细菌产生广谱β-内酰胺酶（ESBLs）。 ESBLs是质粒介导的β-内酰胺酶，能够水解青霉素，头孢菌素和几种非β-内酰胺抗生素。这项基于实验室的研究旨在比较阿克拉ESBL和非ESBL生产者之间的耐药率。四百K。肺炎和大肠杆菌。在Korle Bu教学医院收集了大肠杆菌分离株，并使用磁盘组合方法和Vitek 2系统对ESBL和非ESBL生产者进行了筛选。使用Vitek 2 System确定了17种常用抗生素的最低抑制浓度（MIC）。结果表明，除丁胺卡那霉素和亚胺培南外，ESBL生产者与非ESBL生产者之间的耐药性差异显着（P <0.05）。 198种非ESBL表型对头孢噻肟4（2％），头孢他啶4（2％），呋喃妥因6（3％），阿莫西林/克拉维酸27（13.6％），庆大霉素34（17.2％）和庆大霉素34。环丙沙星78（39.4％）。相比之下，202家ESBL生产商对头孢噻肟197（97.5％），头孢他啶175（86.6％），呋喃妥因94（46.5％），阿莫西林/克拉维酸64（31.7％），庆大霉素166（82.2％）和庆大霉素具有较高的抗药性环丙沙星161（79.7％）。头孢菌素和呋喃妥因适用于非ESBL产生者的治疗，而亚胺培南和丁胺卡那霉素是治疗ESBL产生感染的首选药物。基于证据的抗生素使用将有助于控制ESBL生产商在加纳阿克拉的耐药性传播。另外，需要加强对使用天然产物治疗ESBL感染的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号